- Home
- BBAR vs ZLAB Comparison
BBAR vs ZLAB Comparison
Compare BBAR & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BBAR
- ZLAB
- Stock Information
- Founded
- BBAR 1886
- ZLAB 2013
- Country
- BBAR Argentina
- ZLAB China
- Employees
- BBAR N/A
- ZLAB N/A
- Industry
- BBAR Commercial Banks
- ZLAB Biotechnology: Pharmaceutical Preparations
- Sector
- BBAR Finance
- ZLAB Health Care
- Exchange
- BBAR Nasdaq
- ZLAB Nasdaq
- Market Cap
- BBAR 2.7B
- ZLAB 1.8B
- IPO Year
- BBAR N/A
- ZLAB 2017
- Fundamental
- Price
- BBAR $13.57
- ZLAB $31.24
- Analyst Decision
- BBAR
- ZLAB Strong Buy
- Analyst Count
- BBAR 0
- ZLAB 4
- Target Price
- BBAR N/A
- ZLAB $52.50
- AVG Volume (30 Days)
- BBAR 597.6K
- ZLAB 976.3K
- Earning Date
- BBAR 11-19-2024
- ZLAB 11-12-2024
- Dividend Yield
- BBAR 12.13%
- ZLAB N/A
- EPS Growth
- BBAR N/A
- ZLAB N/A
- EPS
- BBAR 0.24
- ZLAB N/A
- Revenue
- BBAR $2,631,545,762.00
- ZLAB $322,711,000.00
- Revenue This Year
- BBAR N/A
- ZLAB $48.34
- Revenue Next Year
- BBAR N/A
- ZLAB $47.12
- P/E Ratio
- BBAR $22.13
- ZLAB N/A
- Revenue Growth
- BBAR N/A
- ZLAB 28.16
- 52 Week Low
- BBAR $3.86
- ZLAB $13.48
- 52 Week High
- BBAR $14.45
- ZLAB $36.60
- Technical
- Relative Strength Index (RSI)
- BBAR 66.75
- ZLAB 70.41
- Support Level
- BBAR $11.22
- ZLAB $31.52
- Resistance Level
- BBAR $14.45
- ZLAB $36.60
- Average True Range (ATR)
- BBAR 0.63
- ZLAB 1.36
- MACD
- BBAR 0.21
- ZLAB 0.34
- Stochastic Oscillator
- BBAR 70.11
- ZLAB 58.60
About BBAR Banco BBVA Argentina S.A. ADS
Banco BBVA Argentina SA is a banking services provider in Argentina. It provides financial assistance to large corporations, small and medium-sized companies, as well as individuals. It bank provides services through retail, corporate, investment banking, and Small and medium-sized companies divisions. Through the retail banking segment, it provides banking products and services to individuals, corporate banking deals with services to corporates, and the small and medium-sized companies segment focused on foreign trade, agricultural business, and digital products.
About ZLAB Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-2306 for treatments across multiple solid tumor types including ovarian and certain types of breast and lung cancers; ZL-2401 which is an antibiotic in a new class of tetracycline derivatives; and ZL-2301 is an oral, small molecule which targets HCC.